CO2021004004A2 - Composición tópica inyectable - Google Patents

Composición tópica inyectable

Info

Publication number
CO2021004004A2
CO2021004004A2 CONC2021/0004004A CO2021004004A CO2021004004A2 CO 2021004004 A2 CO2021004004 A2 CO 2021004004A2 CO 2021004004 A CO2021004004 A CO 2021004004A CO 2021004004 A2 CO2021004004 A2 CO 2021004004A2
Authority
CO
Colombia
Prior art keywords
injection
topical composition
dca
dry powder
present
Prior art date
Application number
CONC2021/0004004A
Other languages
English (en)
Inventor
Jae Young Kim
Jeong Sun Nam
Original Assignee
Jetema Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jetema Co Ltd filed Critical Jetema Co Ltd
Publication of CO2021004004A2 publication Critical patent/CO2021004004A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN La presente invención hace referencia a una formulación de polvo seco para inyección de un ingrediente DCA. La presente invención es una formulación de polvo seco que tiene una excelente estabilidad de almacenamiento, un pH de 8,2 o menos, de modo que, cal disolverse en agua para inyección, el dolor se reduce durante la inyección al formar un entorno de pH más cercano al del cuerpo humano que el las inyecciones convencionales y permite que el DCA se disuelva bien en el agua de inyección sin precipitarse.GG
CONC2021/0004004A 2019-02-08 2021-03-30 Composición tópica inyectable CO2021004004A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190015232A KR102064864B1 (ko) 2019-02-08 2019-02-08 국소 주사용 조성물
PCT/KR2020/001686 WO2020162685A1 (ko) 2019-02-08 2020-02-06 국소 주사용 조성물

Publications (1)

Publication Number Publication Date
CO2021004004A2 true CO2021004004A2 (es) 2021-05-31

Family

ID=69158535

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0004004A CO2021004004A2 (es) 2019-02-08 2021-03-30 Composición tópica inyectable

Country Status (8)

Country Link
US (1) US20210220260A1 (es)
EP (1) EP3871661A4 (es)
JP (1) JP7224687B2 (es)
KR (1) KR102064864B1 (es)
CN (1) CN112955125B (es)
BR (1) BR112021008420A2 (es)
CO (1) CO2021004004A2 (es)
WO (1) WO2020162685A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102064864B1 (ko) * 2019-02-08 2020-01-10 (주)제테마 국소 주사용 조성물
WO2021172897A1 (ko) * 2020-02-26 2021-09-02 주식회사 엘지화학 데옥시콜릭산을 포함하는 약제학적 조성물
CN116617160A (zh) * 2023-07-25 2023-08-22 山东则正医药技术有限公司 水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010045518A (ko) * 1999-11-05 2001-06-05 이규현 프로포폴의 안정화된 주사제용 약제학적 조성물 및 그의제조방법
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
WO2011092690A1 (en) * 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
CN108619089A (zh) 2011-08-23 2018-10-09 凯瑟拉生物制药有限公司 脱氧胆酸和其盐的制剂
KR101932247B1 (ko) * 2012-05-17 2018-12-21 (주)아모레퍼시픽 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법
EP3145515B1 (en) * 2014-06-27 2023-07-05 Medytox Inc. Formulations comprising cholate and/or chenodeoxycholate for non-surgical removal of a localized fat deposit
MX2018005628A (es) * 2015-11-04 2018-08-01 Kythera Biopharmaceuticals Inc Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof
KR102093872B1 (ko) * 2017-07-03 2020-03-27 진호성 지방제거용 주사제 조성물 및 이의 제조방법
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
KR102064864B1 (ko) * 2019-02-08 2020-01-10 (주)제테마 국소 주사용 조성물

Also Published As

Publication number Publication date
EP3871661A4 (en) 2022-07-13
JP7224687B2 (ja) 2023-02-20
CN112955125A (zh) 2021-06-11
JP2022506578A (ja) 2022-01-17
CN112955125B (zh) 2024-05-28
US20210220260A1 (en) 2021-07-22
KR102064864B1 (ko) 2020-01-10
BR112021008420A2 (pt) 2021-09-14
EP3871661A1 (en) 2021-09-01
WO2020162685A1 (ko) 2020-08-13

Similar Documents

Publication Publication Date Title
CO2021004004A2 (es) Composición tópica inyectable
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
EA201490802A1 (ru) Препараты этанерцепта, стабилизированные меглюмином
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
UY37789A (es) Nuevos derivados de azaquinolina
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
CO2023008949A2 (es) Forma cristalina de tolebrutinib, método de preparación y uso de la misma
CO2020013876A2 (es) Nuevos derivados de quinolina
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
BR112022020315A2 (pt) Novos compostos anti-helmínticos
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112022000914A2 (pt) Composição farmacêutica
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
MY193963A (en) Composition for treating joint diseases and kit containing same